CTLA4 and neoplasm: ICIs selectively restore and normalize the body’s immune responses by disrupting the immunoinhibitory signals mediated by PD-1, PD-L1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in the tumor microenvironment (2).